BCM
AYTU icon

Bridgeway Capital Management’s AYTU BioPharma AYTU Stock Holding History

Bridgeway Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,058
Closed -$161K – 1335
2021
Q1 		$161K Buy
+1,058
New +$168K ﹤0.01% 1297

Other funds holding AYTU

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bridgeway Capital Management's AYTU Position: Q2 2021 in Review

Bridgeway Capital Management sold out of AYTU BioPharma (AYTU) in Q2 2021, closing a stake of 1,058 shares — an estimated $161K sold.

Bridgeway Capital Management first reported a position in AYTU in Q1 2021 and held it in 1 quarter. The position peaked at $161K in Q1 2021. 50 funds tracked by Wall St. Rank hold AYTU as of Q2 2021.

  • Bridgeway Capital Management reported no remaining AYTU BioPharma position as of Q2 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,058 AYTU BioPharma shares in Q2 2021, an estimated $161K.
  • Bridgeway Capital Management first reported a position in AYTU BioPharma in Q1 2021 and held it in 1 quarter.
  • Bridgeway Capital Management's AYTU BioPharma position peaked at $161K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2021.

Based on Bridgeway Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.